XOMA Royalty Corporation

XOMA Royalty Corporation is a biotech royalty aggregator that acquires economic rights to future milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company focuses on early to mid-stage clinical assets, primarily in Phase 1 and 2, with commercial sales potential that are licensed to sponsors or developers. It also acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. XOMA's portfolio includes various assets across multiple therapeutic areas. The company operates in the United States, Switzerland, the Asia Pacific, and Australia.

XOMA Royalty Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol XOMA. The stock trades in US dollars (USD). As a US-based company listed on a major US exchange, its financial reporting and share pricing are denominated in USD, making it accessible to investors through standard US brokerage accounts.

XOMA Royalty Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotech royalty aggregator, it sits at the intersection of finance and biotechnology, generating revenue by acquiring rights to future milestone payments and royalties from drug development programs. This model allows XOMA to participate in the potential upside of multiple therapeutic candidates without bearing the full cost and risk of drug development.

XOMA Royalty Corporation is headquartered in Emeryville, California, United States. The company was incorporated in 1981 and was formerly known as XOMA Corporation before rebranding in July 2024. It serves markets in the United States, Switzerland, the Asia Pacific region, and Australia. Its global presence allows it to source royalty and milestone opportunities from biotechnology companies worldwide.

XOMA Royalty Corporation generates revenue by acquiring economic rights to future milestone and royalty payments from biotechnology companies. It focuses on early to mid-stage clinical assets (Phase 1 and 2) with commercial sales potential, as well as late-stage clinical and commercial assets. By aggregating a diversified portfolio of these rights, XOMA earns income when its partner companies achieve development milestones or generate product sales. The company's portfolio includes various assets across different therapeutic areas, providing multiple potential revenue streams.